Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Companies Infectious Diseases

Innoviva Aims For A First-In-Class Antibiotic

  • News

Executive Summary

Zoliflodacin could become the first new antibiotic for treating gonorrhea in decades, but can it change guidelines?

You may also be interested in...



Altimmune Regains Some Momentum

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

Corporate VCs Play A Bigger Role In Hard Times

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy

Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Companies Infectious Diseases
Latest Headlines

Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

Pipeline Watch: Eight Approvals And 15 Phase III Trial Updates

See All
UsernamePublicRestriction

Register

SC149304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By